Tenax Therapeutics (TENX)

Tenax Therapeutics' (TENX) CEO John Kelley on Q4 2016 Results - Earnings Call Transcript
March 21, 2017 | Price: Free! | Source: Seeking Alpha

Tenax Therapeutics' (TENX) CEO John Kelley on Q3 2016 Results - Earnings call Transcript
Nov. 10, 2016 | Price: Free! | Source: Seeking Alpha

Tenax Therapeutics' (TENX) CEO John Kelley on Q2 2016 Results - Earnings Call Transcript
Aug. 11, 2016 | Price: Free! | Source: Seeking Alpha

Tenax Therapeutics' (TENX) CEO John Kelley on Q1 2016 Results - Earnings Call Transcript
May 19, 2016 | Price: Free! | Source: Seeking Alpha

Tenax Therapeutics' (TENX) CEO John Kelley on 2015 Transitional Report and Corporate Update (Transc
March 16, 2016 | Price: Free! | Source: Seeking Alpha

Tenax Therapeutics' (TENX) CEO John Kelley on Q2 2016 Results - Earnings Call Transcript
Dec. 15, 2015 | Price: Free! | Source: Seeking Alpha

Tenax Therapeutics' (TENX) CEO John Kelley on Q1 2016 Results - Earnings Call Transcript
Sept. 14, 2015 | Price: Free! | Source: Seeking Alpha

Tenax Therapeutics' (TENX) CEO John Kelley on Q4 2015 Results - Earnings Call Transcript
July 16, 2015 | Price: Free! | Source: Seeking Alpha

Tenax Therapeutics' (TENX) CEO John Kelley on Q3 2015 Results - Earnings Call Transcript
March 18, 2015 | Price: Free! | Source: Seeking Alpha

Tenax Therapeutics' (TENX) CEO John Kelley on Q2 2015 Results - Earnings Call Transcript
Dec. 17, 2014 | Price: Free! | Source: Seeking Alpha

Tenax Therapeutics' (TENX) CEO, John Kelley on Q1 2015 Results - Earnings Call Transcript
Sept. 24, 2014 | Price: Free! | Source: Seeking Alpha

Oxygen Biotherapeutics' (OXBT) Management Discusses Q4 2014 Results - Earnings Call Transcript
July 29, 2014 | Price: Free! | Source: Seeking Alpha

Oxygen Biotherapeutics, Inc. The Wall Street Analyst Forum Call Transcript
Nov. 18, 2008 | Price: Free! | Source: Seeking Alpha

Sorry, no schedule available for this company

Tenax Announces Publication Titled “Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial ” - April 9, 2021

Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders - April 7, 2021

Tenax Therapeutics Reports Fiscal Year 2020 Results and Provides Business Update - March 31, 2021

Tenax Therapeutics to Present at the H.C. Wainwright Global Life Sciences Virtual Conference - March 4, 2021

Tenax Therapeutics, Inc. Expands Board of Directors - March 2, 2021

Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med - Jan. 20, 2021

Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med - Jan. 19, 2021

Tenax Therapeutics Reports Third Quarter 2020 Results and Provides Business Update - Nov. 16, 2020

Tenax Therapeutics to Host Virtual R&D Webinar with Scientific Experts Highlighting HELP Study Results - Nov. 6, 2020

Tenax Therapeutics Gains North American Rights to Oral Levosimendan through Expanded License Agreement with Orion Corporation - Oct. 15, 2020

Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting - Oct. 2, 2020

Tenax Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference - Sept. 1, 2020

Tenax Announces Late-Breaking Results from the HELP Study Accepted for Presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting - Aug. 31, 2020

Tenax Therapeutics Reports Second Quarter 2020 Results and Provides Business Update - Aug. 17, 2020

Tenax Therapeutics Expands Board of Directors with the Appointment of Two New Directors, Steven Boyd and Keith Maher, MD - July 20, 2020

Tenax Therapeutics Announces $8.0 Million Registered Direct and PIPE Offerings Priced At-the-Market Under Nasdaq Rules - July 6, 2020

 


Feedback